From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Keep Moving Even when you are playing or at school, try to keep your body moving
Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: a population-based cohort study
they work by mimicking the effects of the GLP-1 hormone, which the body produces naturally and helps regulate appetite and blood sugar
10.1038/s41573-019-0053-0 19 El-LebedyD